--- title: "Dentsply Sirona | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 880 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285266786.md" datetime: "2026-05-05T20:55:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285266786.md) - [en](https://longbridge.com/en/news/285266786.md) - [zh-HK](https://longbridge.com/zh-HK/news/285266786.md) --- # Dentsply Sirona | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 880 M Revenue: As of FY2026 Q1, the actual value is USD 880 M, beating the estimate of USD 840.08 M. EPS: As of FY2026 Q1, the actual value is USD -0.05, missing the estimate of USD 0.0347. EBIT: As of FY2026 Q1, the actual value is USD -18 M. DENTSPLY SIRONA Inc. reported total net sales of $880 million for the first quarter of 2026, a 0.1% increase year-over-year, but a -6.7% decrease on a constant currency basis . #### Segment Revenue - **Connected Technology Solutions (CTS)**: Net sales were $246 million in Q1 2026, a 4.4% increase as reported, but a -2.9% decrease on a constant currency basis, primarily due to lower volumes of imaging products and instruments . - **Essential Dental Solutions (EDS)**: Net sales were $350 million, a -0.9% decrease as reported and a -7.2% decrease on a constant currency basis, mainly due to lower volumes in the Americas and EMEA . - **Orthodontic and Implant Solutions (OIS)**: Net sales decreased to $199 million, an -8.1% reported decrease and a -13.5% constant currency decrease, driven by the absence of Byte products and lower implant product volumes . - **Wellspect Healthcare**: Net sales increased to $85 million, representing a 15.0% increase as reported and a 3.4% increase on a constant currency basis, attributed to new product launches and increased volumes . #### Geographic Net Sales - **Americas**: Net sales decreased to $330 million in Q1 2026 from $364 million in Q1 2025 . - **EMEA**: Net sales increased to $435 million in Q1 2026 from $407 million in Q1 2025 . - **APAC**: Net sales increased to $115 million in Q1 2026 from $108 million in Q1 2025 . #### Operational Metrics - **Net Loss Attributable to DENTSPLY SIRONA**: The company reported a net loss of -$10 million for Q1 2026, compared to a net income of $20 million in Q1 2025 . - **Gross Profit**: Gross profit decreased by -$39 million to $427 million in Q1 2026 from $466 million in Q1 2025, an -8.3% change . - **Gross Profit Margin**: The gross profit margin was 48.5% in Q1 2026, down from 53.0% in Q1 2025, a decrease of -450 basis points, primarily due to lower volumes and higher tariff costs . - **Operating Loss**: Operating loss was -$35 million in Q1 2026, a significant change from an operating income of $63 million in Q1 2025 . - **Selling, General, and Administrative (SG&A) Expenses**: SG&A expenses decreased by -$7 million to $351 million in Q1 2026 from $358 million in Q1 2025, a -2.0% change, driven by lower headcount and marketing expenses . - **Research and Development (R&D) Expenses**: R&D expenses increased by $8 million to $44 million in Q1 2026 from $36 million in Q1 2025, a 22.0% increase, reflecting increased capital allocation to R&D for DS Core and project acceleration . - **Restructuring and Other Costs**: These costs significantly increased to $67 million in Q1 2026 from $9 million in Q1 2025, primarily due to severance costs from the 2026 restructuring plan . - **Segment Adjusted Operating Income (Loss)**: - **Connected Technology Solutions**: Reported an operating loss of -$6 million in Q1 2026, compared to an income of $7 million in Q1 2025, due to lower net sales volumes and higher tariff costs . - **Essential Dental Solutions**: Operating income decreased to $121 million in Q1 2026 from $135 million in Q1 2025, driven by lower net sales volumes and higher tariff costs . - **Orthodontic and Implant Solutions**: Operating income decreased to $8 million in Q1 2026 from $37 million in Q1 2025, primarily due to lower net sales volumes and the absence of Byte product sales . - **Wellspect Healthcare**: Operating income decreased to $23 million in Q1 2026 from $26 million in Q1 2025, impacted by higher tariff costs and unfavorable supply chain changes . - **Interest Expense, Net**: Increased to $24 million in Q1 2026 from $19 million in Q1 2025, mainly due to higher interest rate debt . - **Other (Income) Expense, Net**: Recorded as -$17 million in Q1 2026, compared to $0 million in Q1 2025, including a $14 million benefit from net investment hedges . - **Effective Income Tax Rate**: The rate for Q1 2026 was 76.3%, up from 56.8% in Q1 2025, primarily driven by changes in valuation allowances . #### Cash Flow - **Net Cash Provided by Operating Activities**: Increased to $40 million in Q1 2026 from $7 million in Q1 2025, driven by lower accounts receivable and prepaid expenses . - **Net Cash Used in Investing Activities**: Increased to -$53 million in Q1 2026 from -$17 million in Q1 2025, due to higher capital expenditures of $33 million and a -$7 million net investment hedge settlement . - **Net Cash Used in Financing Activities**: Increased to -$119 million in Q1 2026 from $123 million provided in Q1 2025, primarily reflecting repayments on borrowings . - **Cash and Cash Equivalents**: Ended Q1 2026 at $190 million . #### Unique Operational Metrics - **Days Sales Outstanding (Accounts Receivable)**: Remained at 62 days at March 31, 2026, consistent with December 31, 2025 . - **Days of Sales in Inventory**: Remained at 131 days at March 31, 2026, consistent with December 31, 2025 . - **Deferred Revenue**: Contract liabilities totaled $70 million (Accrued liabilities) and $32 million (Other noncurrent liabilities) at March 31, 2026, with approximately $36 million of previously deferred revenue recognized as net sales in Q1 2026 . #### Outlook and Strategy DENTSPLY SIRONA Inc. approved a 2026 restructuring plan expected to incur $60 million to $65 million in non-recurring charges and generate $120 million in annualized cost savings, with a portion reinvested into innovation and education . The company estimates capital expenditures for 2026 to be $125 million to $150 million, and plans to maintain R&D investment at least 5% of annual net sales . The Board of Directors eliminated quarterly dividends starting Q1 2026, and the company expects to finance operating cash requirements from current cash, cash flows, and existing borrowing facilities . ### Related Stocks - [XRAY.US](https://longbridge.com/en/quote/XRAY.US.md) ## Related News & Research - [Dentsply Sirona misses Q1 revenue, adjusted EPS estimates; backs FY view](https://longbridge.com/en/news/285258334.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md) - [Autohome Inc. to Announce First Quarter 2026 Financial Results on May 28, 2026 | ATHM Stock News](https://longbridge.com/en/news/286390966.md)